Brand name: Esmosec 20
Generic Name: Esomeprazole
Therapeutic Class: Antiulcerant
Strength: 20 mg Tab. (4×10’s)
Mechanism of Action
Esmosec 20 is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esmosec 20 blocks the final step in acid production, thus reducing gastric acidity.
- Treatment of Gastroesophageal Reflux Disease (GERD)
-Healing of Erosive Esophagitis
-Maintenance of Healing of Erosive Esophagitis
-Symptomatic Gastroesophageal Reflux Disease
- H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Acid Related Dyspepsia
Duodenal and Gastric Ulcer
- Dosage and administration
Tablet/Capsule: Esmosec 20 delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating.
Administration IV injection must be administered intravenously over a period of at least 3 minutes. Half of the IV injection should be used when 20 mg is to be administered. Prepared solution must be used within 12 hours of preparation and can be exposed to normal indoor lighting at a maximum of 30 °C.
- Side Effects
- In general, Esmosec 20 was well tolerated in both short- and long-term clinical trials. The most frequently occurring adverse events ( >1%) are
- headache and diarrhea
- abdominal pain
- constipation and dry mouth occurred at similar rates among patients taking Esmosec 20.
- Dosage & Administratio
- Esmosec 20 delayed release tablet should be swallowed whole and taken at least one hour before eating.
- The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.
- If symptoms do not resolve completely after 4 weeks, an additional 4 weeks of treatment may be considered.
- Esmosec 20 is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.
- Use in Pregnancy & Lactation
- Pregnancy: There are no adequate and well-controlled studies on the use of Esomeprazole in pregnant women. Therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk. Esomeprazole should be used during pregnancy only if the potential benefit to pregnant women justifies the potential risk to the fetus
- Lactation: Esomeprazole is excreted in human milk. Thus, a decision should be taken to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.